CytRx Begins Aldoxorubicin Phase 2 Study

CytRx highlighted that ImmunityBio and NantKwest announced the initiation of a Phase 2 randomized, two-cohort, open-label study for first and second-line treatment of locally advanced or metastatic pancreatic cancer (QUILT-88). The study has received FDA authorization and will initially enroll 268 subjects across both cohorts. They indicated enrollment expected to begin in June 2020.

This study follows upon the January 2020 announcement of a complete response in Metastatic Pancreatic Cancer in one patient who received its experimental cancer therapy in its Phase 1 clinical trial.

"We continue to be encouraged with the progress and results of this promising treatment and protocol, which includes aldoxorubicin, in targeting pancreatic cancer, the third leading cause of cancer-related death in the U.S.", said Steven A. Kriegsman, CytRx's Chairman and CEO.

CytRx out-licensed global development, manufacturing, and commercialization rights for aldoxorubicin to ImmunityBio Inc. in July 2017. CytRx has an agreement with ImmunityBio that will pay CytRx up to $343 million in milestones, plus single and double-digit royalties on aldoxorubicin.